Medley Indústria Farmacêutica Ltda is the third largest pharmaceutical company in Brazil. Our good performance is due mainly to the generic medicines market – where we are the leaders since 2002. in 2009, Medley sales were BR$ 458 million.

With two manufacturing plants in Campinas/SP (main offices) and Sumaré/SP, Medley produces pills, capsules, coated pills, liquids, balms, creams, and suspensions. In total, including our sales force teams, Medley employs around 1,500 persons.

Medley's success is directly related to its coherent management style, that values social projects, and to our Human Resources policy, which is dedicated to internal growth and the personal and professional development of our people. For six times the company was elected as one of the best 150 Places to Work by Guia Exame (Editora Abril) in Brazil (2002, 2003, 2004 e 2006, 2007, and 2008).

Respect, innovation, quality, effectiveness. These adjectives may seem wide-ranging, but all are complementary and help translate what Medley represents in the Brazilian Generic Medicine Market. The company was the first to be approved by the Federal Government to perform its own pharmaceutical equivalence testing, and, even before the approval of Generic Medicines in Brazil, we performed a relevant role in campaigns to help in supplying affordable and quality products to the Brazilian population, with the continued intent to making good health accessible to all. The wide portfolio of Generic Medicines from Medley (189 products) is entirely produced within the rigorous standards of quality set by Anvisa. Additionally, the company works towards the awareness of the importance of medical guidance, of correct pharmaceutical assistance, and of the quality of life offered by generic medicines. The acknowledgement to this work can be observed in our leadership in medical prescriptions, which directly reflects in the market. Currently of the 20 best-selling generic medicines in the country, 13 are from Medley. Medley has made large investments in pharmaceutical bio-equivalence and equivalence, in addition to having acquired high-technology equipment, and is capable of developing and producing a diversified lineup of generic medicines with the same effectiveness and safety of the reference products, but at very affordable prices.

As in any international development project, to blaze the trail and especially know the market wherein we were entering was key. Additionally, the Brazilian regulation requirements meant that the company had one of the best pharmaceutical portfolios in the world, with medicines accepted without requiring many adaptations on various countries with large potential export markets.

Providing health and well-being to the largest possible number of persons. That is the guideline that moves Medley on all our communications actions. In fact, the company reinforces its institutional image with athletic sponsorships. To Medley, associating our brand and products to sports and athletes is a way to foster the practice of sports, and to reinforce the benefits of a healthier lifestyle.

The search for sustainability, that is, the continuation of the business of our company without negatively affecting the future generations, and assuring our needs are met with balanced actions in the present, is another great aspiration of Medley.

Currently, the company already develops projects that look to increasingly strengthen the relationships and publicize the principle of the Global Pact and the Millennium Goals, establishing social, environmental, and economic indicators to promote and consolidate this issue amongst our stakeholders. Medley was one of the first companies in its industry in Brazil to adopt the Guidelines form the GRI (the Global Reporting Initiative) for its Social Responsibility report, which translates our concern in making our actions transparent to all our stakeholders.

Medley Indústria Farmacêutica Ltda is a company from the Sanofi. The company is the market leader in Generic Medicines in Brazil since 2002, with a portfolio of 189 products. In 2008, the company sales amounted to BR$ 458 million.

Medley owns two manufacturing plants. In our main plant, located in Campinas, we produce pills, capsules, coated pills, liquids, balms and creams. In Sumaré/SP, we produce capsules and suspensions.

Sanofi is a world leader in the pharmaceutical industry and research, developing and publicizing therapeutic solutions to improve the lives of people. The Group is an open-capital enterprise with shares traded in the Paris and New York stock exchanges.

In Brazil, the Sanofi is the leader in the pharmaceutical market, with nearly 12 per cent market share. In the country since the end of the 1950's, Sanofi Brasil provides a wide portfolio of branded, OTC, and generic medications, as well as vaccines, through its Sanofi Pasteur division.

With the acquisition of Medley on April 2009, the Sanofi now employs over 3,800 persons in Brazil and has a local production capacity of over 300 million units per year, thanks to the units in Suzano (Sanofi), and Campinas and Sumaré (Medley).